Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
393
datasets available to search
ShareScore release 0.9.0
Dataset results
393 results for “mRNA vaccine”
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
ClinicalTrials.gov study NCT05868382. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
ClinicalTrials.gov study NCT05217641. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
ClinicalTrials.gov study NCT05249829. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection
Open the record for dataset details and reuse information.
Dataset for: mRNA vaccine quality analysis using RNA sequencing
Open the record for dataset details and reuse information.
Data for: Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2
Open the record for dataset details and reuse information.
Dataset and additional info for "Serious adverse events of special interest following mRNA vaccination in randomized trials" (Fraiman et al. 2022)
<p>Dataset for:</p> <p>Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022 Aug 30;40(40):5798–805. doi: 10.1016/j.vaccine.2022.08.036. Epub ahead of print. PMID: 36055877; PMCID: PMC9428332. <a href="https://doi.org/10.1016/j.vaccine.2022.08.036">https://doi.org/10.1016/j.vaccine.2022.08.036</a> </p>
Innate immune responses against the mRNA component of mRNA vaccine promote cellular immunity through IFN-β at the injection site
Open the record for dataset details and reuse information.
Dataset related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"
<p>This record contains data related to article “Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases”</p> <p>The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (<em>p</em> &lt; 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of &gt;1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80-98, <em>p</em> &lt; 0.0001). Moreover, in the seroconverted patients, a daily dose of &gt;1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of &gt;1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.</p> <p>.</p>
CD4+ and CD8+ T cell responses to peptides covering SARS-CoV-2 Spike in response to mRNA vaccination in persons recovered from SARS-CoV-2 infection
<p>These files contain intracellular cytokine staining flow cytometry data for CD4+ and CD8+ T cells after exposure of serial PBMC to SARS-CoV-2 spike peptides or control antigens. PBMC are from subjects recovered from SARS-CoV-2 infection that subsequently received mRNA vaccination. The data were analyzed and exported from FlowJo version 10 as individual gated events and related Boolean subsets for four functional markers: CD40L, IFN-g, IL-2, and TNF-a. Counts and frequencies are both included.</p> <p> </p> <p><strong>Procedure for obtaining data:</strong></p> <p>Cryopreserved peripheral blood mononuclear cells (PBMC) were thawed and rested overnight. PBMC (1 x 10<sup>6</sup> per well) were stimulated with a SARS-CoV-2 spike overlapping peptide pool (JPT, 1 μg/mL each peptide; 0.4% final DMSO concentration), 0.4% DMSO as a negative control, or PHA-P (Remel; 1.6 μg/mL final concentration) as a positive control, in the presence of anti-CD28 and anti-CD49d (BD Biosciences) antibodies at 37°C for 6 hours. Brefeldin A (Sigma) was added after 2 hours. Cells were stained with Live/Dead Near IR dye (Invitrogen), treated with FACS lyse (BD Biosciences) and frozen at -80<sup>o</sup>C. For staining, the cells were thawed, washed, and permeabilized with Permeabilizing solution 2 (BD Biosciences) then stained with fluorochrome labeled monoclonal antibodies to anti-human CD3 mAb (clone UCHT) conjugated with PE-Texas Red (ECD; Beckman Coulter), anti-human CD4 mAb (clone SK3) conjugated with BV510 (Biolegend), anti-human CD8 mAb (clone SK1) conjugated with PerCP-Cy5.5 (BD Biosciences), and the activation markers anti-human CD40L mAb (clone TRAP1) conjugated with BV421 (BD Biosciences), anti-human IFNγ mAb (clone 4S.B3) conjugated with PE (BD Biosciences), anti-human IL2 mAb (clone MQ1-17H12) conjugated with APC (BD Biosciences), and anti-human TNFα mAb (clone MAb11) conjugated with FITC (BD Biosciences). Events were recorded with BD Fortessa and analyzed with FlowJo (v10 for Mac; BD). </p>
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
ClinicalTrials.gov study NCT05308680. IPD Sharing: NO. Countries: 1. Publications: 1.
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
ClinicalTrials.gov study NCT07053072. IPD Sharing: NO. Countries: 1. Publications: 13.
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
ClinicalTrials.gov study NCT00204607. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
ClinicalTrials.gov study NCT05272605. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
ClinicalTrials.gov study NCT04798027. IPD Sharing: YES. Countries: 4. Publications: 0.
Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old
ClinicalTrials.gov study NCT05186571. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
ClinicalTrials.gov study NCT03468244. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
ClinicalTrials.gov study NCT05483725. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
ClinicalTrials.gov study NCT05436834. IPD Sharing: Not stated. Countries: 7. Publications: 1.
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ClinicalTrials.gov study NCT06602024. IPD Sharing: Not stated. Countries: 11. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.